English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Public Opinion Is Shifting on Psilocybin and Psychedelic Medicine
Something quietly remarkable has been happening in how Americans talk about psychedelics. Not so long ago, the phrase “magic mushrooms” showed up in conversations alongside tie-dye and Grateful Dead bootlegs. Now it shows up in clinical trials, state ballot measures, and — increasingly — at kitchen tables where someone is wondering whether psychedelics might help a sibling who can't shake their depression, or a parent stuck in addiction, or themselves. Polling backs up the shift. In a Hill-HarrisX survey, roughly 35% of U.S. voters said psychedelic substances like psilocybin have a legitimate medical use. The other 65% disagreed. That split sounds lopsided until you remember the same question, asked a decade earlier, would have produced numbers so small they'd barely register. A third of the country now sees psychedelics as medicine. That's a meaningful cultural moment, and it has direct consequences for anyone weighing whether to attend a psychedelic retreat or pursue plant medicine as part of their healing. The poll cracks open along familiar lines. Among Democrats, 43% accept that psychedelics have medical applications. Independents land at 41%. Republicans sit lower, around 23%. Age matters even more than party. A majority of 18-to-29-year-olds — 53% — say psychedelics belong in medicine. Older cohorts mostly still disagree, though the gap is closing as research piles up. What's driving the younger numbers isn't recreational nostalgia. It's exposure. Younger adults have grown up reading about ketamine clinics, MDMA trials for PTSD, and the steady drumbeat of psilocybin studies coming out of major universities. They've watched friends try microdosing for anxiety. They've seen veterans on podcasts describe ayahuasca and ibogaine as the things that finally cracked their armor when nothing else did. The cultural script has changed, and the poll is the lagging indicator. The science isn't speculative anymore. Imperial College London's Centre for Psychedelic Research ran a head-to-head trial comparing psilocybin therapy with escitalopram — one of the most widely prescribed SSRIs on earth — in patients with moderate-to-severe major depressive disorder. Psilocybin held its own. On several measures, it pulled ahead. Robin Carhart-Harris, who led that work, has been pretty direct about the implication: psilocybin therapy may belong earlier in the treatment ladder for depression, not as the last resort after years of failed pills. That's a significant claim, and it's being taken seriously by regulators and clinicians who, a decade ago, wouldn't have returned the call. Beyond depression, the evidence is mounting across several conditions: None of this means psychedelics are a miracle. They aren't. What they appear to be is a genuinely new class of mental-health tool that works through mechanisms ordinary antidepressants don't touch — neuroplasticity, ego dissolution, emotional reprocessing, and what many practitioners call contact with the master plants themselves. While the federal government still classifies psilocybin and most other psychedelics as Schedule I, the ground is moving locally. Oregon became the first state to legalize psilocybin for supervised therapeutic use. Oregon also decriminalized personal possession of small amounts of psilocybin, alongside Washington, D.C. Denver, Santa Cruz, Oakland, and a growing list of municipalities have either decriminalized or deprioritized enforcement around mushrooms. For readers researching retreats, this matters in practical ways. It means access to legal or quasi-legal psilocybin experiences inside the United States is no longer purely theoretical. It also means the international retreat scene — Peru, Costa Rica, the Netherlands, Mexico, Jamaica — is no longer the only option for people who want a structured, supervised psychedelic experience. That said, the international scene is still where the deepest traditions live, particularly for ayahuasca, San Pedro, and ibogaine. Here's the thing nobody really tells you in the news articles: a polling number doesn't make a retreat safer or more legitimate. Public opinion is a tailwind, not a quality-control mechanism. As psychedelics get more mainstream, the number of retreat centers has exploded — and not all of them are run by people who know what they're doing. If you're weighing whether to book something, a few honest questions to sit with: The angle that keeps drawing new attention is addiction. The standard recovery model — detox, twelve steps, maybe some therapy — works for a lot of people and fails a lot of others. The failure rate is part of why ibogaine clinics in Mexico have waiting lists full of Americans who've tried everything else. It's also why psilocybin-assisted therapy for alcohol use disorder has produced some of the most compelling clinical results in the entire psychedelic field. Plant medicine doesn't replace recovery work. People who treat ayahuasca or ibogaine as a one-shot cure tend to be disappointed, and sometimes worse. But for those willing to do the integration, the therapy, the lifestyle changes — psychedelics can crack open a door that conventional treatment couldn't budge. That's the part the polling numbers don't fully capture: not just that people believe psychedelics have medical value, but that a growing community of people credit them with saving their lives. The 35% number will keep climbing. As more states follow Oregon's lead, as more clinical trials report out, as more veterans and grieving parents and people in long-term recovery tell their stories publicly, the cultural ground will keep moving. The interesting question isn't whether psychedelic medicine becomes mainstream — that's already happening. The question is whether it gets integrated thoughtfully, with proper screening, real training, and respect for the traditions these substances come from, or whether it gets steamrolled by venture capital and turned into another wellness commodity. For now, the people researching retreats are part of that answer. The questions you ask, the centers you support, the standards you hold facilitators to — those things shape what this field becomes. If something in this article has nudged you closer to exploring further, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.
Kambo Safety: The Real Risks Behind the Frog Medicine Trend
A woman in her late thirties walks into a sharehouse on the north coast of New South Wales. She's there to sit for kambo — the secretion of an Amazonian tree frog, dabbed into small burns on her skin. She's done it before. She trusts the woman administering it. A few hours later she's dead on the floor, and her housemate is on the phone to triple-zero because the person running the ceremony doesn't know the number and doesn't own a phone. That's not a hypothetical. That's the case the NSW state coroner ruled on, and the findings should be required reading for anyone thinking about kambo, ayahuasca, or any plant medicine ceremony run outside the bounds of medical oversight. The coroner's language was unusually direct: vulnerable people are putting their trust in self-styled healers who don't have basic first aid training, and the risks of kambo are being underestimated by the people promoting it. If you're reading this because you're weighing a retreat, or because a friend has been raving about how kambo changed their life, slow down. This one's worth thinking through. Kambo is the waxy secretion of Phyllomedusa bicolor, the giant monkey frog of the Amazon basin. Indigenous groups in the region — the Matsés, Katukina, Yawanawá and others — have used it for generations, traditionally before hunting, to sharpen the senses and clear what they describe as panema, a kind of bad luck or heaviness. The frogs are tied to sticks, their backs scraped, and the dried secretion is later applied to small burns on the skin of the recipient. What happens next is intense and fast. Within seconds of application, the peptides in the secretion hit the bloodstream. Blood pressure crashes or spikes. The face swells. People vomit, sometimes violently. There can be diarrhea, sweating, racing heart, panic, a sense of overwhelming heat. The acute phase is usually short — twenty to forty minutes — but those minutes are not gentle. In the West, kambo has been folded into the broader neo-shamanic scene and marketed as a deep physical and spiritual cleanse. You'll see claims about boosting the immune system, clearing addiction, treating depression, even helping with cancer. Here's the part the coroner was explicit about: there is no credible research supporting those medicinal claims. There is, however, documented evidence of harm. Kambo contains a cocktail of bioactive peptides — dermorphin, deltorphin, phyllomedusin, phyllokinin, sauvagine and others. Some are being studied for legitimate pharmaceutical reasons. But the dose in a ceremony isn't measured. The peptide concentration varies frog to frog, batch to batch, practitioner to practitioner. You don't know what you're getting. The physiological strain is real. Kambo can trigger severe hyponatremia (low sodium) if practitioners encourage the loading of water beforehand — a practice that has killed people. It puts stress on the cardiovascular system. It can interact dangerously with prescription medications, particularly antidepressants and blood pressure drugs. People with cardiac conditions, epilepsy, recent surgeries, or who are pregnant should not go near it. And here's the thing — most ceremony providers don't do a serious medical screen. They ask a few questions. They take your word for it. Adverse events documented in the medical literature include seizures, psychosis, kidney injury, esophageal tears from violent vomiting, syndrome of inappropriate antidiuretic hormone secretion, and sudden cardiac death. The Australian Therapeutic Goods Administration eventually classified kambo as a Schedule 10 poison — the most restrictive category, meaning substances of such danger to health that their sale, supply and use should be prohibited. That's not a regulator being squeamish. That's a regulator looking at a death toll. The deeper problem the coroner pointed at isn't kambo itself — it's the parallel economy of self-credentialed healers, priestesses, maestras and shamans that has grown up around plant medicines in the last two decades. Someone takes a two-week course online, designs a website, picks a Spanish or Quechua honorific, and starts charging for ceremonies. This isn't gatekeeping for its own sake. Indigenous traditions that work with kambo, ayahuasca, or peyote involve years of apprenticeship, often a lifetime, with extensive teaching about dosage, contraindications, energetic management, and crucially what to do when something goes wrong. A two-week certificate doesn't replicate that. Neither does charisma. Neither does a beautiful altar. The case in NSW is bleak on this point. The person administering kambo at the fatal ceremony admitted she didn't know the emergency number. She didn't have a phone. The recipient herself had just completed a short practitioner course and was, on the day, leading the session. Two people, neither equipped for what was about to happen, in a sharehouse, with no medical backup. The result is exactly what you'd expect when you remove every safeguard. None of this means every retreat is a death trap. Reputable plant medicine retreats — including ayahuasca centers in Peru, ibogaine clinics in Mexico, and psilocybin retreats in the Netherlands and Jamaica — operate with screening protocols, medical staff on site, and clear emergency procedures. They're not hard to identify if you know what you're looking for. Some questions worth asking any retreat or practitioner before you hand over money: If the answers are vague, defensive, or wrapped in spiritual language designed to make you feel like asking is beneath the work — walk away. A serious practitioner welcomes those questions. They've thought about them more than you have. It would be easy to read a story like this and decide all plant medicine is reckless. That's not quite right either. Ayahuasca, psilocybin, ibogaine, and other psychedelic substances are being studied with increasing seriousness for addiction, treatment-resistant depression, PTSD, and end-of-life anxiety. Some of the early clinical data is genuinely promising. People do find their lives reorganized by these experiences in ways they couldn't access through talk therapy alone. But the gap between a well-run clinical or ceremonial container and a sharehouse ritual run by an under-qualified practitioner is enormous. The medicine isn't the only variable. Set, setting, screening, dosage, facilitation, and aftercare matter as much as the substance itself — often more. The deaths and serious injuries that make headlines almost always involve a breakdown somewhere along that chain, not the molecule acting alone. Kambo is a particular case because the claimed benefits are largely unsupported by research while the physiological risks are well documented. That's a worse risk-benefit profile than most of the classical psychedelics. If you're drawn to the idea of a deep cleanse or a hard reset, there are safer roads to walk down — including ones that involve less dramatic medicines or none at all. The woman at the center of the coroner's findings was, by every account, kind, smart, in pain, and looking for a way through. That's most of the people I meet at retreats. The pull toward plant medicine isn't usually about thrill-seeking — it's about real suffering and the sense that conventional options have run out. That's a sympathetic, human place to be. It's also a place where you're easy to take advantage of. Pain makes us bad consumers. We grasp at the first practitioner who speaks the right language, lights the right candles, says the right things about our wounded inner child. The work of choosing well — slowly, with skepticism intact — is part of the medicine itself. Maybe the first part of it. If you're researching plant medicine because something in your life is genuinely stuck, take the time to do it properly. Read inquest findings. Read peer-reviewed studies. Talk to people who've sat with the practitioner you're considering, ideally years after their ceremony, not weeks. And if you do want to explore vetted ayahuasca, psilocybin, or other plant medicine retreats with proper screening and integration support, you can browse our marketplace here and compare options without the pressure. The medicine isn't going anywhere. Take your time.
How Psilocybin Rewires the Brain: The Science Behind Magic Mushrooms
Something strange happens when a person takes psilocybin and slides into a scanner. The brain doesn't shut off, doesn't go quiet, doesn't even slow down. It starts talking to itself in ways it normally never does. Regions that have spent a lifetime ignoring each other suddenly strike up a conversation. And researchers — peering at the colorful tangle of connections on their screens — are beginning to understand why this might matter for people stuck in depression, addiction, or the kind of looping self-criticism that refuses to let go. Magic mushrooms have been having a moment in serious science for a while now. Not the giggly college-dorm version. The clinical, peer-reviewed, MRI-machine version. And the picture emerging from that research is genuinely interesting, even for readers who have no intention of ever eating a mushroom. Psilocybin appears to temporarily reorganize how information moves through the brain — and that reorganization may be the reason it shows up in study after study as a promising tool for psychedelic healing. Here's the short version. Psilocybin, the main psychoactive compound in roughly two hundred species of mushroom, doesn't simply jam a signal or flood the brain with serotonin. It rewires the traffic patterns. A study published in the Journal of the Royal Society Interface compared brain scans of volunteers given intravenous psilocybin against those given a placebo, and the contrast was striking. The psilocybin group's brains didn't just light up more — they lit up differently, forming connections across regions that normally don't communicate. Imagine the brain as a city with established roads. Information takes the same routes every day, from the same neighborhoods to the same destinations. Psilocybin doesn't bulldoze the roads. It just builds a bunch of temporary side streets — improvised shortcuts that link parts of town that have never had any reason to talk to each other. The visual cortex starts chatting with the language areas. The number-processing region exchanges notes with the color-perception region. A mathematician sees the digit seven and registers it as glowing teal. Synesthesia, for a few hours, becomes neurology. And — this is the part that surprised the researchers — the new pattern wasn't chaos. It wasn't random noise. The activity formed distinct cycles, organized differently from the brain's everyday default, but organized nonetheless. The brain on psilocybin isn't broken. It's running on a different operating system. For decades, neuroscientists have been mapping what they call the default mode network — a set of brain regions tied together by our ongoing internal monologue. The default mode network is where the self lives, more or less. It's where you ruminate, where you replay the embarrassing thing you said in 2014, where you rehearse what you'll say to your sister at Thanksgiving. In healthy people it hums along quietly in the background. In depressed people, it often won't shut up. The neuroscientist David Nutt and colleagues at Imperial College London found that psilocybin quiets activity in this region — sometimes dramatically. Nutt's framing is memorable: people stuck in depressive thinking have brains that are overconnected in the self-referential loop. The same thoughts grind around the same neural grooves until those grooves are canyons. Negative self-talk becomes the only road in town. Loosen those overworn paths, the theory goes, and you give the brain a chance to settle into a new arrangement. A growing body of clinical work on plant medicine for addiction and treatment-resistant depression points in the same direction. Smokers who can't quit. Drinkers who've tried everything. People with end-of-life anxiety from a terminal cancer diagnosis. Across these very different populations, a small number of well-supervised psilocybin sessions seem to produce shifts that years of conventional treatment didn't. That doesn't mean psilocybin is a miracle compound or that anyone should be self-medicating. The contexts that produce these outcomes are tightly controlled: clinical screening, trained guides, hours of preparation, a calm setting, integration sessions afterward. The drug is a tool. The framework around it does most of the work. Psilocybin isn't operating in a vacuum. The same research wave that's revived interest in mushrooms has put ayahuasca, ibogaine, San Pedro, and other master plants back on the table — sometimes in laboratories, sometimes in retreat centers in the Amazon, sometimes both. Each substance has its own pharmacology and its own cultural lineage, but the underlying observation is similar: certain compounds, used carefully, can temporarily quiet the rigid self and let the mind reorganize. This is roughly what indigenous traditions have been describing for centuries, just in different vocabulary. Where a neuroscientist says diminished default-mode-network activity, an ayahuasquero might say the medicine showed someone where they were stuck. The phenomena being described aren't that far apart. What's new is that we now have brain scans backing up what curanderos have claimed for generations. If you're reading this because you're personally considering a retreat — and a lot of people researching this topic are — it's worth knowing what the science says and what it doesn't say: People often want a preview, which is understandable but also a little funny — like asking someone to describe a flavor you've never tasted. Still, certain themes show up again and again in trip reports from clinical trials and ceremony settings. A loosening of the usual sense of self. A widening of perspective. Emotions that feel both bigger and more workable than usual. Visuals, sometimes, though not always the cartoon kind people expect. One often-quoted account comes from a cancer patient in a New York University study who said something inside him simply snapped, and his anxieties stopped looking like things to defend against. That kind of shift is hard to engineer through talk therapy alone. It's not that psilocybin gives people new information. It seems to give them new access to information they already had — buried under layers of habit and self-protection. Researchers at Johns Hopkins followed volunteers a year after their psilocybin sessions and found that nearly two-thirds rated the experience among the most meaningful of their lives. Personality tests showed lasting increases in openness — a trait that doesn't usually budge much after early adulthood. Whatever the brain is doing on psilocybin, some of it appears to stick. Mushroom ceremonies sit in an awkward legal patchwork. They're criminalized in most of the United States, decriminalized in a few cities, legal for therapeutic use in Oregon, and openly practiced in places like Jamaica, the Netherlands, Mexico, and Costa Rica. Plenty of well-run retreats exist outside the U.S., and the better ones look more like a thoughtfully facilitated medical-and-spiritual program than a party. A few honest things to think about before booking anything. Are you currently on SSRIs or other psychiatric medications? You'll need to discuss this with both your prescriber and the retreat's medical team — sudden withdrawal carries its own risks. Have you done your psychological homework? A retreat is not a substitute for therapy; it's something that pairs well with therapy. Can you commit to the integration work afterward? The month following a psychedelic experience is when most of the actual change happens, or doesn't. For readers who want to look further into this, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision — a good retreat will still be there next month, and the work you do beforehand tends to shape what you bring home.
What a Clinical Psilocybin Session Actually Feels Like, Start to Finish
If you've been reading about psilocybin therapy and wondering what actually happens during one of those clinical sessions — the ones the headlines describe in vague, reverent terms — you're not alone. The reporting tends to focus on outcomes: depression lifting, terminal patients making peace with their illness, lifelong drinkers walking away from the bottle. What rarely gets explained is the granular, hour-by-hour reality. The room. The pill. The playlist. The two people sitting quietly nearby while your interior world rearranges itself. I've spent enough time around psychedelic researchers and retreat facilitators to know that the experience is engineered far more carefully than most people assume. Psilocybin, the active compound in magic mushrooms, behaves very differently in a controlled therapeutic container than it does at a music festival. And for anyone weighing whether a retreat or trial might fit their own situation, knowing what those eight or nine hours actually look like matters more than another abstract piece about neuroplasticity. Researchers running modern psilocybin studies — and the reputable plant-medicine retreats that follow their lead — obsess over two words: set and setting. Set is your mindset walking in. Setting is the physical and human environment around you. Get either one wrong and the same dose that produces a breakthrough for one person can produce a long, frightening afternoon for another. This is a big part of why clinical sessions and well-run retreats look nothing like the chaotic mushroom experiences people sometimes describe from college. There's no crowd. No flashing lights. No phone buzzing on the nightstand. The room is usually softly lit, often with a couch, a blanket, eyeshades, and headphones. Two trained sitters — typically with therapy backgrounds — stay with you the entire time, mostly silent, available if you need them. It's worth pausing on that last part. The sitters aren't there to guide you in any active sense. They're there so that if something difficult comes up — a panic spike, a wave of grief, a memory you didn't expect — there's a calm human nearby to remind you that you're safe and that whatever you're feeling will pass. That presence alone changes the chemistry of the experience. Before anyone hands you a capsule, you'll spend hours in conversation. In the Johns Hopkins protocol that's become the template for much of this work, participants typically meet with their two monitors for around eight hours across several sessions before the first dose. You talk about your life. Your reasons for being there. What scares you. What you hope to find. You get walked through what the experience may feel like — the visual shifts, the time distortion, the emotional weather. The instructions participants are given tend to boil down to three words: trust, let go, be open. Simple to say, harder to actually do when you're three hours into a session and your sense of self is dissolving. But repeating those words to yourself in the difficult moments turns out to be surprisingly effective. If you're considering a retreat rather than a clinical trial, the preparation phase is one of the clearest tests of whether the operation is legitimate. Reputable retreats schedule real conversations with you in advance, ask about your medications and mental-health history, screen for contraindications like a personal or family history of psychosis, and don't simply hand you a brew because you paid the deposit. If a place skips that step, walk away. On dosing day, you arrive having eaten lightly. You settle onto the couch. You're given a capsule. In the Hopkins studies, the therapeutic dose was calibrated around 20 milligrams of psilocybin for a 70-kilogram person — roughly 154 pounds. That's enough to reliably produce what researchers carefully call a mystical-type experience, but notably less than the doses associated with difficult trips, which tend to cluster around 30 milligrams or higher. For the first twenty to forty minutes, nothing happens. This is the strangest part for first-timers — the waiting. Then it begins. Most people describe an initial body sensation, a kind of warm pressure, followed by visual softening at the edges of the room. By the one-hour mark you're well inside it. You put on the eyeshades. You put on the headphones. The playlist used in the Hopkins and NYU trials runs about eight hours and weaves together classical pieces by composers like Górecki, Bach, and Beethoven, Indian devotional chants, new-age compositions, and music from around the world. It isn't background. The music becomes structure — something to ride when the experience gets big. One of the practical reasons researchers favor psilocybin over LSD is right there in that timeline. A psilocybin session fits inside a single day. LSD can stretch to twelve hours, which is a long time to hold a therapeutic container — and a long time for a participant to stay in deep process. The patients I've read transcripts of, and the retreat participants I've interviewed over the years, describe remarkably consistent themes. A felt sense that everything is connected. An encounter with grief or fear that somehow doesn't crush them. A perspective shift on a relationship, a regret, a long-held story about themselves. Many describe meeting their illness face-to-face and coming to a kind of truce with it. One woman in the Hopkins cancer-anxiety study, Sherry Marcy, had been living under what she called a cloud of doom after an endometrial cancer diagnosis. After her psilocybin session she described the cloud lifting — reconnecting with her family, her children, her ordinary wonder at being alive. She wasn't cured of cancer. She was returned to her own life while she still had it. That distinction matters. Patrick Mettes, who took part in the parallel NYU trial before dying in 2012, compared the launch of his experience to a space shuttle leaving the clunky trappings of earth behind for the weightlessness above. His widow has said that perspective shift helped them both live fully right up to the end. These aren't promises of healing — they're testimony that the experience can change a person's relationship to suffering, which is often the more honest goal. If you're choosing between a research trial (very hard to get into) and a retreat (much more accessible), it helps to understand how they differ. Clinical sessions are usually one-on-one or two-on-one, indoors, on a couch, with eyeshades and a fixed playlist. Retreats — particularly psilocybin retreats in the Netherlands, Jamaica, or Mexico — tend to run small groups of six to twelve, often combine psilocybin with breathwork, integration circles, and somatic practices, and span several days rather than a single afternoon. Neither format is universally better. The clinical model offers tight safety and screening but limited continuity afterward. The retreat model offers community, often multiple sessions across a week, and dedicated integration time — but quality varies wildly between operators. A few questions worth asking before you book anywhere: The session is the easy part. Integration is where the work actually lives. A profound afternoon under psilocybin can deliver insights at a velocity your normal life isn't built to absorb, and without deliberate follow-through those insights tend to fade into the same drawer where last year's New Year's resolutions went. Good integration usually involves some combination of journaling, conversations with a therapist or coach familiar with psychedelics, body-based practices like yoga or somatic experiencing, and time in nature. It's slow. It's often unglamorous. It's where the cloud-lifting feeling becomes durable change, or doesn't. Anyone selling you a one-and-done miracle is selling you something else. If a supervised psilocybin journey is something you're seriously weighing — for depression, for end-of-life distress, for the kind of stuck pattern that hasn't budged for years — the most useful thing you can do next is read widely, talk to people who've actually been through it, and choose a setting that matches your temperament and your medical reality. For readers who want to take this further, a range of carefully vetted psilocybin retreats can be browsed on our marketplace here. The research is genuinely promising. The experience is genuinely powerful. And the difference between a session that changes your life and one that doesn't usually comes down to the unglamorous details — preparation, container, dose, sitters, integration — long before anyone swallows anything.
How to Dry Magic Truffles Properly: A Practical Storage Guide
If you've ever ordered fresh magic truffles and watched them slowly turn into a sad, slimy lump at the back of the fridge, you already know the problem. Fresh truffles are alive. They breathe, they sweat, and they have a shelf life roughly equivalent to a punnet of strawberries. Drying them isn't just a storage hack — it's the difference between a clean, potent psilocybin experience six months from now and tossing fifteen euros of wasted mycelium into the bin. This guide walks through how to dry magic truffles properly at home, why the method matters for potency, and a few honest caveats most articles skip. I'll also touch on where dried truffles fit into the broader plant medicine conversation — because if you're reading this, there's a decent chance you're already curious about what these little sclerotia can do. Fresh magic truffles — the underground sclerotia of certain Psilocybe species, most commonly Psilocybe tampanensis or Psilocybe hollandica — contain a surprising amount of water. We're talking roughly 70% moisture by weight. That water is great for the truffle while it's growing, but once it's harvested and sealed in a vacuum pack, it becomes a problem. Mould loves moisture. Bacteria love moisture. Your truffles, unfortunately, do not love mould or bacteria. Vacuum-sealed fresh truffles, kept in a cold fridge, will give you maybe four to eight weeks of decent shelf life. After that, even unopened, you'll start to notice spots, slime, or a smell that tells you something has gone very wrong. Once you open the pack, you're looking at a week, tops. Drying solves all of this. Properly dried truffles drop to around 5–10% moisture, which is far too dry for microbial life. Stored well, they'll keep their psilocybin content for a year or more. Some people report decent potency after two years in airtight, light-free storage. The catch — and it's an important one — is that doing it wrong can destroy the active compounds you're trying to preserve. Psilocybin and psilocin are the two main psychoactive compounds in magic truffles. Both are sensitive to heat. Push the temperature too high — above roughly 50°C / 122°F — and you start degrading the very chemistry that makes the truffle worth keeping. People have tried microwaving truffles, baking them in the oven at 100°C, even using hair dryers. The results range from disappointing to genuinely useless. The principle to internalise is simple: dry slowly, at low temperatures, with good airflow. Anything that sounds like a shortcut probably isn't. Drying truffles well takes between 12 hours and several days depending on your method and the local humidity. Plan for that, and you'll be fine. This is the gentlest method, the one that preserves the most potency, and the one most experienced users recommend. It's also the slowest. Break your truffles into pieces no thicker than a peanut. Bigger lumps hold moisture in the centre and risk mould before they dry through. Lay the pieces out on a wire rack or a sheet of kitchen paper, well spaced — they shouldn't touch each other. Put the rack somewhere warm, dry, and dark. A linen cupboard is perfect. Above a radiator (not on it) in winter works well too. Leave them alone for 24 to 48 hours, turning the pieces once or twice. You're looking for what's called "cracker dry" — the truffles should snap cleanly when bent, not bend. If they bend at all, they're not done. This stage is where people get impatient and ruin their batch. Resist that urge. If you live somewhere humid — coastal climates, the UK in autumn, basically anywhere damp — pure air drying can stall. The truffles get to a leathery state and just sit there, slightly tacky, refusing to crisp up. A small desk fan solves this beautifully. Same setup as before — broken truffles on a wire rack — but with a fan blowing across them on the lowest setting. Don't aim hot air at them. Just moving room-temperature air is enough. This usually cuts drying time to 12–18 hours. Once they're cracker dry, you move to the most important step: the final cure. Here's where most home dryers stop, and it's why their truffles lose potency faster than they should. Cracker-dry truffles still contain a small percentage of residual moisture — enough to slowly degrade psilocybin over months in storage. The cure removes that last bit. Put your dried truffles in an airtight jar with a desiccant — food-grade silica gel sachets work, or you can buy small calcium chloride canisters from any homebrewing or food-storage supplier. The desiccant should be in its own little container or wrapped in a bit of paper towel so it doesn't touch the truffles directly. Seal the jar. Leave it for another 24 to 48 hours. What you'll get at the end is what people sometimes call "bone dry" — truffles so dehydrated they're brittle and almost weightless. This is the state you want for long-term storage. Stored in a cool, dark place in a sealed container with a fresh desiccant, they'll hold their potency for a year easily, often longer. One thing worth mentioning, because it trips up a lot of people: a dried truffle is much lighter than a fresh one. If a recipe or experience report references "15 grams of fresh truffles", that's roughly equivalent to 4–5 grams dried, since you've removed about 70% of the original weight as water. The psilocybin content per truffle hasn't changed — you've just concentrated it into less mass. So if you're used to dosing by fresh weight and you switch to dried, scale down accordingly. People have surprised themselves badly by treating dried weights like fresh ones. A scale that reads to 0.1g is essential here, not optional. Magic truffles occupy an interesting legal grey area — in the Netherlands they're sold openly because they were never specifically banned the way the mushroom fruiting bodies were. For people curious about psilocybin but unable or unwilling to travel for a formal psychedelic retreat, truffles have become a kind of accessible entry point. They're milder gram-for-gram than dried mushrooms, more predictable in dose, and legal to purchase in a handful of European countries. That said, doing this work alone in your living room is a different proposition from doing it with experienced facilitators in a held container. Psilocybin can surface difficult material, and integration matters. If you're drawn to plant medicine for something deeper than curiosity — addiction patterns you can't shake, depression that hasn't responded to anything else, trauma you can't outrun — a structured retreat is usually a better starting point than a solo session with dried truffles from your cupboard. For readers who want to take this further with proper support, a range of curated psilocybin and plant medicine retreats can be browsed on our marketplace here. Either way: dry your truffles properly, store them better than you think you need to, and treat what's in the jar with the respect it deserves.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
The Psychedelic Gold Rush: What the Wall Street Bet on Plant Medicine Means for Retreat-Seekers
A few years back, a former Goldman Sachs partner stood in front of a room full of hedge fund executives in Miami and told them, with the casual confidence of someone who's already placed his chips, that psychedelics would be the next short-term bubble. He wasn't talking about ayahuasca ceremonies in the Peruvian jungle. He was talking about IPOs, FDA pathways, and patent portfolios. And he was right — sort of. That moment, more than almost any other, marked the point where psychedelics stopped being a fringe wellness curiosity and became a serious investment category. Compass Pathways did go public. ATAI Life Sciences followed. MindMed listed on the Nasdaq. Billions of dollars poured into research labs trying to figure out how to turn magic mushrooms and ibogaine into prescription medicine. And for people quietly researching whether to book a retreat for their depression, addiction, or grief, this matters more than you might think. Here's the thing, though. The Wall Street story and the retreat-seeker story are not the same story. They share vocabulary. They sometimes share science. But they're aimed at completely different outcomes, and confusing one for the other can lead you to make a bad decision about your own healing. The bull case is straightforward. Depression affects hundreds of millions of people globally. Conventional antidepressants help maybe a third of patients meaningfully, and roughly another third get partial relief. That leaves an enormous population — people with treatment-resistant depression, PTSD, addiction, end-of-life anxiety — for whom modern psychiatry has very little to offer. Early clinical trials with psilocybin, MDMA, and ibogaine have produced results that, frankly, look almost too good. Single-digit numbers of sessions producing remission rates that pharmaceutical companies usually dream about. If you're an investor, that's a market measured in tens of billions. If you're a patient, it's something else entirely — it's the first piece of genuinely new mental health science in fifty years. Both things can be true at once. The awkward part is that they create very different incentives. Pharmaceutical companies want patentable molecules, controlled dosing, standardized protocols, and reproducible outcomes. They want a pill, or as close to a pill as the FDA will allow. They are not, generally speaking, interested in a Shipibo curandero singing icaros over you for six hours in a wooden maloca. That's a feature, not a bug, of how drug development works. But it does mean the medicalized version of psychedelics that eventually reaches your psychiatrist's office will look almost nothing like a traditional plant medicine retreat. What Novogratz called an awakening — the recognition that ayahuasca, psilocybin mushrooms, and the iboga root from West Africa have real medicinal potential — isn't new to anyone who's spent time in indigenous healing traditions. The Shipibo, the Bwiti, the Mazatec, and dozens of other cultures have known this for centuries. The novelty is that Western institutions like Johns Hopkins and Imperial College London are now publishing the data that confirms what these traditions have always claimed. This is where master plants come into the conversation. In the Amazonian tradition, plants like ayahuasca, chacruna, bobinsana, and tobacco aren't just chemicals — they're considered teachers, beings with their own intelligence that work with you over time through a structured process called dieta. A retreat-seeker considering ayahuasca needs to understand this framing exists, even if they don't fully buy into it, because the people pouring the brew at most reputable retreats absolutely do. For addiction recovery in particular, the picture has been quietly remarkable. Ibogaine, derived from the iboga root, has shown the ability to interrupt opioid dependence in ways no pharmaceutical has matched — often in a single, intense session. Ayahuasca centers in Peru and Costa Rica have hosted people fighting alcohol dependence, cocaine addiction, and process addictions with outcomes that, while not formally measured the way a clinical trial would measure them, are striking enough that researchers have started taking them seriously. The investment boom is reshaping the retreat landscape in ways most prospective participants don't see. Some changes are good. Some are decidedly not. On the good side: more public conversation has meant more transparency, better screening protocols at reputable retreats, and a slow professionalization of integration services. Five years ago, finding a therapist who would seriously discuss your ayahuasca experience without recommending an inpatient psych ward was difficult. Now they exist in most major cities. That's progress. On the less good side: money attracts opportunists. The number of new retreats opening every year has exploded, and not all of them are run by people with the experience, training, or ethics the work requires. I've sat in ceremonies led by maestros with forty years in the tradition, and I've heard horror stories about weekend operators who learned the medicine from a YouTube playlist. The gap between those two ends of the spectrum is enormous and, for an untrained eye, surprisingly hard to spot from a glossy website. Here's what I'd actually look at when researching a psychedelic retreat: Cost ranges vary wildly. A week-long ayahuasca retreat in Peru typically runs anywhere from $1,500 at simpler centers to $4,500 at more elaborate ones. Ibogaine clinics, because they require medical supervision, sit higher — usually $5,000 to $10,000 for a treatment program. Psilocybin retreats in the Netherlands, Jamaica, or Costa Rica generally fall between $2,000 and $5,000. None of this is cheap, and the cheap options often aren't the bargain they appear to be. One thing the Wall Street narrative tends to flatten is the difference between taking a psychedelic compound in a clinical setting and sitting in ceremony with a plant medicine. Both can be healing. They are not the same experience. The clinical model, which is what Compass Pathways and similar companies are building toward, looks like this: you arrive at a medical office, take a measured dose of a synthesized molecule, lie on a couch with eyeshades and a curated playlist, and have a trained therapist sit with you. It's regulated, repeatable, and increasingly likely to be covered by insurance. For people with severe treatment-resistant depression who would never set foot in a jungle lodge, this model is going to be a genuine breakthrough. The ceremonial model is something else. You're typically away from home for a week or more. You eat a restricted diet for days beforehand. You drink the medicine in a group, often through the night, accompanied by songs and prayers that come from a specific cultural tradition. You purge — usually physically, sometimes emotionally, often both. The context, the community, and the cultural container are considered as important as the substance itself. Neither approach is universally better. They serve different needs. If your goal is to address clinical depression in a structured medical setting, the clinical path may suit you. If your goal is something messier — a confrontation with patterns you can't seem to break, grief you haven't been able to metabolize, a sense that your life has drifted from anything resembling meaning — the ceremonial path tends to do that work in a way no clinic currently replicates. Was Novogratz right that psychedelics would become a short-term bubble? Partly. Several listed psychedelic companies have had brutal stock performance since their initial euphoria. The science, meanwhile, has continued to mature. MDMA-assisted therapy for PTSD came close to FDA approval and may yet get there. Psilocybin therapy programs are advancing through trials. Ibogaine is finally getting serious clinical attention in the United States after decades of being treated as fringe. For the retreat-seeker, the financial drama is mostly noise. What matters is that the cultural permission to talk about these experiences is wider than it's ever been, the integration ecosystem is more developed, and the research validating what indigenous traditions have long claimed continues to accumulate. None of that guarantees a good experience for you personally. But it does mean you're not stepping into the unknown alone the way someone in 1995 would have been. If something in this piece has nudged you closer to actually doing the work rather than just reading about it, a curated selection of ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine, whichever one you choose, will still be there when you're ready.
Kambo Ceremony, Round Two: Sitting With Fear and the Frog
The second time around, I thought I knew what I was walking into. I didn't. That's the thing about kambo — and most plant medicine, really. You show up with one set of expectations and the medicine quietly hands you a different agenda. My first kambo journey had been intense but luminous. I left it feeling scrubbed clean from the inside, hyper-aware of what my body wanted to eat, drowning in something close to self-love. So when two old friends — both deep in shamanic ceremony for years — invited me over for an afternoon sit, I said yes almost reflexively. Sunday afternoon. Bike ride away. Empty calendar. Why not? Be careful what you wish for. My friend opened the door and I felt the fear arrive before I'd even taken off my shoes. Bodies remember. Mine remembered the bottles of water lined up like soldiers, the bucket waiting nearby, the heat that climbs up the arm and settles inside the skull. For a second I genuinely thought about turning around. Going home. Saying I forgot something. But I was there. The soup was on the stove. My friends were smiling. And honestly — last time had been beautiful. Hard, yes. But beautiful. How much worse could a second round be? The four of us sat in a circle inside what used to be a classroom, now part of an artist commune. Feathers on the walls, dream catchers, the smell of old wood. A friend handed me a small carved frog made of green stone — jade or something similar. Whoever held the frog got to speak. The others listened. It's a simple device but it does something to a room. “What's your intention?” he asked. Usually I arrive with a clear one. I'd journaled, I'd thought it through, I knew exactly what I wanted to look at. This time I had nothing. I closed my eyes and waited. The answer surfaced almost on its own: I want to learn how to sit with fear. Not push it away, not perform around it, not make anyone else responsible for it. Just sit with it. I passed the frog along and we smiled at each other across the circle. There's a particular kind of intimacy in admitting your fear out loud to people who aren't going to flinch. Before we got to the kambo, my friend offered rapé. I'd only heard about it a few weeks earlier, which felt like one of those convenient synchronicities the universe occasionally throws your way. For anyone who hasn't come across it: rapé (pronounced ha-PAY) is a finely ground powder made from tobacco mixed with the ashes of certain sacred trees. It's blown into your nostrils through a V-shaped wooden pipe by another person — you can't really self-administer it properly. The active compounds absorb through the nasal tissue and reach the brain almost immediately. She knelt in front of me, knees touching mine, and tipped a small mound of green powder into the pipe. Deep breath in. The pipe against my left nostril. A short, sharp exhale from her end — and the powder hit. The sting climbed straight into my skull. My left eye watered immediately. We did the right nostril next. Then I sat there, mouth open, drooling into the bucket like a baby, while a hot wave rolled up through my torso and into my head. What I didn't expect was the sense of power. Not arrogance — more like a clean, undeniable awareness that there was a serious reservoir of strength inside me. I wanted to bottle it for the days I feel small. The rush peaked, then softened, then left me with this quiet, slightly nauseous clarity. The colors in the room had brightened. The inner critic that usually narrates everything had simply gone quiet. Beautiful, actually. Worth mentioning if you've never tried it: the experience varies wildly depending on the blend, the moment, and who's blowing it. Some people get a clean grounding; others end up vomiting. It's not a party drug. “How many dots, and where?” my friend asked. Traditionally men get them on the upper left arm, women on the lower left leg. He left it open. I noticed my left hand was already gripping my right shoulder, almost without my deciding. So — four dots, right shoulder. He nodded; he'd been thinking the same number. The kambo process itself is straightforward and strange. You drink a lot of water — at least a liter, ideally more — to give the body something to purge. The points are made by lightly burning the top layer of skin with the tip of a smoldering stick. Then a small amount of the frog secretion is placed on each burn. The medicine enters through the lymphatic system, not the bloodstream, which is part of what makes it so fast. I started purging before he'd even finished the burns. The fear I'd named as my intention was already climbing my throat. I made the bucket just in time. My friend laughed gently and told me to keep drinking. So I did. Another liter or so, until any more would have come straight back up. The first dot of medicine touched my skin and the heat went everywhere at once. Down my arm. Up my neck. My face felt like it was inflating. The inside of my mouth swelled — I was briefly relieved I could still breathe through it. My head dropped onto my knee and the fear flooded back in full strength. And here's the part I want to be honest about, because it's the part nobody really markets: I noticed, in that moment, how badly I wanted someone to rescue me. To hold my hand. To say something soothing. To take the feeling away. My friends had offered all of it — they were sitting right there. But I had a choice. Reach for relief, or stay. I stayed. Not heroically. Just stubbornly. I knew the wave would pass. I knew there was no story that needed solving, no version of me that needed saving. I just had to hold my own knees and breathe. After what was probably twenty minutes but felt longer, I crawled to a couch a few meters away. Could not find a comfortable position to save my life. Tried every side, gave up, ended up cross-legged with sun on my closed eyelids. The intensity slowly drained out. My head still felt enormous, but the fear had loosened its grip. When I finally touched my lips, they were not my lips. Kambo sometimes leaves you with what facilitators call frog face — puffy lips, swollen eyelids, the works. It fades within a day or so. I looked in the mirror and laughed. I was grateful I didn't have plans. The whole afternoon had compressed into maybe ninety minutes of actual ceremony, and now we were drifting back into the sharing circle, this time with a huge stuffed frog as the talking object. I looked at the three people in the room and felt like I could actually see them — past the small talk, past the personality, into whatever quiet thing was underneath. That part doesn't translate to writing very well. You either know the feeling or you don't yet. Here's what I wasn't expecting. After my first kambo round, the afterglow had been delicious — clean senses, intuitive eating, a steady hum of self-love. This time, the medicine handed me my intention with both hands. Every fear I had agreed to look at came marching through, one after another, for an entire week. I'm used to emotional weather. This was a storm. But each time a fear surfaced, I remembered the imprint from the ceremony — that I didn't need to leak it onto anyone. I didn't need to find someone to blame, or someone to soothe it for me. I could ask: is this thought actually true? Am I currently making someone else responsible for my own discomfort? It's a useful little knife to carry around. None of which means I sat there silently swallowing everything. Boundaries matter. Desires matter. Expressing them matters. But what happens after you express them isn't yours to control. When you make yourself vulnerable, you're also making yourself reachable — and reachable means occasionally hurt. The medicine didn't make that easier. It just made it more obviously worth it. A few honest notes, because I get asked. Kambo isn't psychedelic — there's no visionary component, no altered headspace in the way ayahuasca or psilocybin produces. It's somatic. Physical. Brutally physical for about thirty minutes. The work happens in the body and in whatever you're forced to confront while your body is busy. It also isn't risk-free. There are real contraindications — heart conditions, low blood pressure, pregnancy, certain medications, recent surgery — and a responsible facilitator will ask about all of them before you sit. If they don't ask, don't sit with them. Hydration matters. Fasting beforehand matters. Sitting with experienced people matters. This is one of those medicines where the difference between a good practitioner and a careless one is significant. And the afterglow, as I learned, isn't guaranteed to be pleasant. Sometimes the medicine clears space; sometimes it surfaces everything that was sitting in that space. Both are useful. Neither is comfortable. If something in this resonates and you want to take a closer look, a range of curated kambo and plant-medicine ceremonies can be explored on our marketplace here. Whatever you choose, choose slowly. The frog will wait.
The Therapist Shortage Hiding Behind the Psychedelic Boom
Walk into any conversation about the future of psychedelics and you'll hear about molecules. MDMA for PTSD. Psilocybin for treatment-resistant depression. Ketamine clinics opening in strip malls next to nail salons. The molecules get the headlines, the venture capital, the breathless press releases. But here's what almost no one talks about at dinner parties: a psychedelic without a trained human sitting beside you is, at best, a chemistry experiment. At worst, it's a crisis waiting to happen. That gap — between the drugs racing through clinical trials and the people who are supposed to administer them — is becoming impossible to ignore. Investors are starting to notice. So are regulators. And so should anyone considering plant medicine, master plants, or any form of psychedelic healing for addiction, trauma, or the kind of stuck life pattern that ordinary talk therapy hasn't budged. Psychedelic-assisted therapy is not like swallowing an antidepressant and waiting six weeks to feel marginally less bad. A single psilocybin session in a clinical setting runs six to eight hours. MDMA sessions can stretch longer. Before any of that, there's preparation — multiple sessions of it. Afterward, integration work that can last weeks or months, where the real change actually happens. None of that runs itself. Each step requires at least one, often two, trained professionals in the room. They aren't just babysitters with clipboards. They're trauma-informed clinicians who know how to hold space when a person is reliving the worst night of their life, how to spot a paranoid spiral before it gets dangerous, and how to translate a chaotic visionary experience into something the person can actually use on Monday morning. That skillset doesn't appear in a weekend workshop. And there is nowhere near enough of it to go around. Industry estimates suggest that if psilocybin and MDMA gain regulatory approval in the coming years — and the trial data has been strong enough that this is no longer a wild guess — the United States alone could need somewhere in the hundreds of thousands of trained psychedelic facilitators. Not 5,000. Not 20,000. Hundreds of thousands. Right now, the number of clinicians with even modest psychedelic training is a tiny fraction of that. A few thousand have completed reputable programs. Many more have done a podcast and called themselves ready. The gap between those two camps is exactly where things tend to go wrong for vulnerable patients. Here's the uncomfortable math: it's relatively cheap to scale a drug. Once a compound is approved, manufacturing it is a logistics problem. Scaling humans is a different beast entirely. You can't 3D-print someone who's done their own deep work, sat with hundreds of journeyers, and knows how to recognize the difference between a productive abreaction and a person who needs to be hospitalized. A small but growing ecosystem of training organizations has emerged to address this. Some are university-affiliated — programs at places like the California Institute of Integral Studies have been quietly turning out psychedelic-assisted therapists for years. Some are run by veterans of the MAPS clinical trials, which means the curriculum is grounded in actual research protocols rather than someone's ayahuasca download. And then there are the startups. Education-focused companies are raising real money to build certificate programs, online curricula, and hybrid in-person trainings designed to onboard thousands of licensed therapists, social workers, and physicians into psychedelic practice. The pitch to investors is straightforward: you can pour millions into a biotech betting on a single compound, or you can fund the training infrastructure that every one of those biotechs will eventually need. What does a good training program actually cover? At minimum: Programs that skip the last bullet are the ones to be wary of. A facilitator who has never had their own ego dismantled tends to flinch at exactly the wrong moment. Most readers thinking about ayahuasca, psilocybin, or ibogaine aren't going to wait around for FDA approval and a clinic in their hometown. They're looking at retreats now, often in Peru, Costa Rica, the Netherlands, Mexico, or Jamaica, where the legal landscape allows real ceremonial work to happen. The therapist-shortage problem doesn't disappear when you cross a border. It changes shape. In the retreat world, the question isn't whether your facilitator has a state license — it's whether they've done years of apprenticeship, whether they understand both the traditional and the psychological dimensions of the work, and whether they can hold the room when things get hard. And things will get hard at some point. That's the work. A few honest questions to ask any retreat before you book: None of this means you shouldn't pursue plant medicine. For people stuck in cycles of addiction, depression, or post-traumatic patterns that haven't responded to anything else, psychedelics can be genuinely life-changing. The research on ibogaine for opioid dependence, psilocybin for end-of-life distress, and ayahuasca for treatment-resistant depression keeps getting more interesting, not less. But the field is in an awkward adolescence. The science is real. The demand is real. The trained workforce is not yet real at the scale it needs to be. That gap is where most of the bad outcomes happen — not from the molecules, but from the humans who weren't ready to hold what the molecules opened up. So if you're researching a retreat, take an extra month. Ask the awkward questions. Read everything the retreat publishes, then read what former participants say in unmoderated forums. Talk to two or three places, not one. The good operators welcome this kind of scrutiny. The shaky ones get defensive. For readers who want to take this further, a curated selection of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here — a useful starting point if you'd rather compare facilitator backgrounds and program structures in one place than chase down a dozen retreat websites yourself. The boom in psychedelics is real. The shortage of people qualified to guide it is also real. Holding both of those truths at once is the most useful thing a thoughtful retreat-seeker can do right now.
Florida's Legal Mushroom Dispensary: What Amanita Muscaria Actually Is
Walk into a small storefront in Tampa and you can buy psychedelic mushrooms over the counter. Legally. No prescription, no clandestine handoff, no Telegram chat with a stranger named Mushroom_Mike. Just gummies, capsules, and powders sitting on a shelf next to the hemp flower. Sounds like the headline every psychedelics watcher has been waiting for, right? Not quite. The mushrooms in question aren't the psilocybin variety that's been making waves in clinical trials and ayahuasca-adjacent retreat conversations. They're Amanita muscaria — the red-capped, white-spotted toadstool you've seen in Mario games and fairy-tale illustrations your whole life. And the legal loophole keeping this shop open says a lot about where psychedelic culture in the U.S. actually stands right now. The dispensary, run by a longtime cannabis activist who cut his teeth fighting for medical marijuana in Florida, started life as a hemp shop in 2018. Mushrooms got added to the product mix more recently. The owner is careful with his language — he doesn't call them “magic” mushrooms in the store, because that word is shorthand for psilocybin, and psilocybin is firmly Schedule I under federal law. Same legal tier as heroin. Possession alone can wreck your life. What he sells instead is Amanita muscaria, a mushroom that's psychoactive but contains no psilocybin. Its active compounds are muscimol and ibotenic acid — different chemistry, different experience, and crucially, not scheduled by the DEA. Federally, it's legal. State-by-state it's legal almost everywhere, with Louisiana being the lone exception. That's the loophole the whole shop hinges on. The product range includes capsules, gummies, powdered extracts, and even mycology kits — the kind you could, in theory, use to cultivate something more potent. Buyers sign a form swearing they won't. Whether anyone actually believes the form does much is another question. This is the part most casual readers miss, and it's the part that matters most if you're researching plant medicine seriously. Amanita muscaria and psilocybin mushrooms are not interchangeable. They're not even close. Psilocybin works on serotonin receptors — the same neighborhood ayahuasca's DMT visits, the same neighborhood LSD and mescaline operate in. The classic psychedelic family. Amanita muscaria, on the other hand, works on GABA receptors via muscimol. The experience people describe is more dissociative, dreamlike, often sedating — sometimes nauseating, sometimes confusing, occasionally just unpleasant. It's been used ritually for centuries in Siberia and parts of Northern Europe, but it never built the kind of therapeutic case study record that psilocybin has. Here's the other thing nobody puts on the gummy label clearly enough: raw Amanita muscaria is toxic. Eat one off the forest floor and you can end up vomiting, hallucinating in distressing ways, or — in rare but documented cases — comatose. The Tampa shop's owner says he sources from Lithuania and processes the mushrooms to reduce ibotenic acid before they reach the shelf. That's standard practice for traditional preparation. It's also entirely dependent on the seller doing it right. The shop owner isn't naive about what he's doing. He hired a lawyer before stocking the product. He notified local law enforcement. His read is straightforward — drugs get banned when they become a public problem, and Amanita muscaria has flown under the radar for decades because almost nobody was using it. The moment it becomes popular, he expects pushback. He's probably right. There's already a quiet pattern of regulators reacting to legal-gray-area substances once they hit critical mass. Kratom, Delta-8 THC, kava bars — every one of them went through a window of accessibility followed by a patchwork of state-level restrictions. Amanita products are next in line if sales scale up. Meanwhile, the broader landscape for psychedelics is shifting in ways that make this Florida experiment look almost quaint: What's happening in Tampa isn't the leading edge of psychedelic policy reform. It's a side door — one entrepreneur testing how much legal weight a technically-legal mushroom can hold. Let's say you read about this and thought, “Huh, maybe I should try an Amanita gummy.” Pause for a second. People researching plant medicine seriously — for depression, addiction, trauma, the stuck-life-pattern stuff most readers are quietly carrying — generally aren't looking for a novelty trip. They're looking for something with a track record. And Amanita muscaria's track record in modern healing contexts is thin. There's traditional Siberian shamanic use, sure. There's anecdotal hobbyist reporting online. There's not much in the way of contemporary therapeutic research, integration frameworks, or experienced facilitators working with it in retreat settings. Compare that to ayahuasca, which has decades of formalized ceremonial structure in the Amazon, a growing body of neuroscience research, and an established retreat infrastructure with facilitators who've sat with hundreds or thousands of participants. Compare it to psilocybin, which is moving through clinical trials and into legal regulated programs. Compare it to ibogaine, which has a niche but well-documented role in interrupting opioid addiction. Amanita doesn't sit in that conversation yet. It might one day. Right now it doesn't. That doesn't mean it's worthless — it means if you're spending money and intentional time on a psychedelic experience aimed at real change, an Amanita gummy from a Florida shop is probably not the tool. A properly run retreat with a tradition behind it almost certainly is. The Tampa dispensary matters less for what it sells and more for what it represents — the cultural appetite for legal access to psychedelics is way ahead of the legal framework. People are walking into a storefront in a state where recreational cannabis is still illegal and buying mushroom gummies. The demand is here. The infrastructure is improvising around the law. That improvisation comes with real risk. Unregulated processing means quality varies wildly. Lack of guidance means people take these substances alone, with no preparation, no integration, no one watching out for them if the experience gets difficult. The retreat model — for all its costs and complications — exists precisely because psychoactive experiences benefit enormously from container, intention, and skilled support. A gummy in your apartment doesn't offer any of that. If you've been reading about psychedelics and feeling the pull toward something deeper than a curious experiment, the better question isn't where can I buy this legally. It's what am I actually hoping to address, and what tradition or modality has the strongest track record for it. For some people that's psilocybin in Jamaica or the Netherlands. For others it's ayahuasca in Peru or Costa Rica. For people working with opioid addiction it might be ibogaine in Mexico. The match matters more than the convenience. For readers who want to take this further, a range of curated ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly — these aren't gummies you grab on a whim.
Psychedelic Therapy Explained: How Plant Medicines Are Treating Depression, Addiction, and PTSD
Something strange has happened in the last decade. Compounds that were exiled from medicine in the 1970s — psilocybin, LSD, MDMA, ayahuasca, ibogaine — are now sitting inside peer-reviewed trials at places like Johns Hopkins, Imperial College London, and NYU. Researchers are publishing results that, frankly, would have been laughed out of a journal twenty years ago. Psychedelic therapy is no longer fringe. It's the most interesting frontier in mental health right now, and for readers weighing whether to attend a retreat, understanding what this kind of work actually involves matters more than the headlines suggest. So let's get into it. Not the hype, not the doom — the practical picture. What psychedelic therapy is, what it's used for, and which master plants and compounds are showing up in the research and on the ground at retreat centers around the world. Forget the cliché of someone in a tie-dye shirt waving sage around. Modern psychedelic therapy is structured, usually clinical or ceremonial in feel, and almost always involves more preparation and integration than the dosing itself. The substance is the catalyst. The therapy is the container. In a typical model, a participant meets with their facilitator or therapist over one or several preparation sessions. They discuss intention, history, fears, what they're hoping to look at. Then comes the dosing session — anywhere from four to twelve hours depending on the medicine — followed by integration sessions in the days and weeks after. That last part is where most of the actual change tends to happen, which is something a lot of first-timers underestimate. Two broad styles dominate the field: Neither approach is objectively better. They serve different people and different problems. A trauma survivor who can't yet tolerate intense altered states may do far better with the psycholytic route. Someone confronting end-of-life dread or treatment-resistant depression often benefits more from the deep, single-encounter model. Here's where the research has gotten genuinely interesting. We're not talking about vague wellness claims — we're talking about randomized trials with measurable outcomes. The reader considering a retreat should know what the evidence actually supports. Over 280 million people globally live with depression, and a meaningful slice of those cases don't respond to SSRIs or talk therapy. Trials with psilocybin-assisted therapy have shown rapid reductions in depressive symptoms — sometimes after just one or two dosing sessions — with benefits lasting six months or longer. Researchers at Imperial College described it as the brain getting a kind of reset. Similar effects have appeared with ayahuasca and, in earlier studies, with LSD. The interesting part isn't just that symptoms drop. It's how fast and how durably they drop compared to conventional medication. Especially in patients facing terminal illness, psilocybin has produced striking reductions in existential anxiety. People stop white-knuckling their diagnosis and find a strange kind of equanimity. For more everyday anxiety — generalized, social — the data is thinner but emerging. Some practitioners report that low-dose psycholytic work helps clients move past the looped thinking that anxiety produces. This is where MDMA-assisted therapy has taken the lead. Trials in veterans, first responders, and survivors of severe trauma have shown sustained remission rates that conventional treatments rarely approach. MDMA seems to dampen the fear response just enough that someone can actually look at their trauma without re-traumatizing themselves in the process. The therapy still does the heavy lifting. The compound just opens the door. This is the area I find most personally moving, partly because conventional addiction treatment has such a brutal failure rate. The numbers here are worth sitting with: The pattern across all of these isn't that the medicine cures addiction. It's that the medicine, combined with serious therapeutic work, gives people a window to see themselves differently — and that window is sometimes enough to break a cycle that nothing else could touch. Different medicines have different personalities. Anyone who's spent time in this world will tell you that. Here's a rough map of which substance tends to be used for which condition, based on current research and field practice. The most widely studied psychedelic for depression and addiction. Sessions typically run four to six hours. The experience is often described as emotionally vivid, occasionally challenging, but more navigable than longer-acting medicines. Many of the well-known retreat centers in the Netherlands and Jamaica work with psilocybin, since it's legally accessible in both contexts. The Amazonian brew combining the Banisteriopsis caapi vine with a DMT-containing companion plant. Strongly associated with deep emotional processing, trauma work, and addiction recovery. Ceremonies usually last four to six hours and are held in traditional or neo-shamanic settings. Ayahuasca demands respect — the dieta, the integration, the lineage of the facilitator all matter. Not a classical psychedelic, but a key player in PTSD treatment. Currently the closest to formal regulatory approval in several countries. Generally used in controlled clinical or clinical-style retreat environments rather than ceremonial ones. A longer, more intense experience — sometimes 24 hours or more — used primarily for opioid dependence. Specialized clinics in Mexico, Costa Rica, and Portugal offer ibogaine programs with proper medical screening. This is not a substance to approach casually. Mescaline-containing cacti used in long-form ceremonies, often outdoors. The experience tends to be gentler emotionally than ayahuasca, more grounded, more heart-centered. Used in various contexts for depression, grief, and general life-direction work. The research is encouraging. It is not a guarantee. A retreat is not a clinical trial. The quality of facilitation, the screening process, the integration support, and your own preparation will shape your experience far more than the substance itself does. A few honest things to weigh before booking anything: People sometimes ask me whether psychedelic therapy is the future of mental health. I think the honest answer is: it's part of the future. It's not going to replace conventional psychiatry, and it shouldn't try to. What it can do — and what the early evidence keeps suggesting — is reach people who haven't been reached by anything else. People with treatment-resistant depression. Veterans whose PTSD won't budge. Addicts who've tried every program available. For those readers especially, it's worth knowing this option exists, and worth doing the homework before stepping into it. If something here resonates and you want to look closer at what's actually available, a curated selection of psychedelic and plant-medicine retreats can be browsed on our marketplace here. The decision deserves time — sit with it, talk to people who've done the work, and trust your own pacing.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
